ChlamyDerm Immune Therapy has been developed against Chlamydia infection that plays a role in atherosclerosis. We have demonstrated in mice the decrease of both inflammation and Chlamydia bacterium in the lung after ChlamyDerm immunization.
Under-reporting of Chlamydia infection is substantial, because most people with chlamydia are not aware of their infections and do not seek testing. Also, testing is not often done if patients are treated for their symptoms. An estimated 2.8 million Americans are infected with chlamydia each year. If left untreated, chlamydial infections can cause serious reproductive and other health problems with both short-term and long-term consequences.
We are developing Chlamyderm based on our technology platform on DermaPrep, Antigeneering and nanomedicine formulation.